Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a clinical-stage precision medicine oncology company focused on discovering and developing targeted small-molecule therapies for biomarker-defined cancers. The company’s core scientific approach is synthetic lethality, aiming to exploit cancer-specific genetic vulnerabilities to improve tumor killing while limiting harm to healthy tissue. Its pipeline has evolved from earlier mutant p53 programs toward DNA damage response, or DDR, pathway targets acquired and advanced after the Atrin transaction in 2022. Aprea remains pre-commercial and is funded primarily through equity financing and grants rather than product sales.

5.63

— Aprea Therapeutics, Inc.
	%
Clinical-stage oncology candidates	0% Small-molecule drug candidates being advanced through preclinical, IND-enabling, and clinical development for biomarker-defined cancers.
DNA damage response inhibitors	70% Programs targeting ATR, WEE1, and related DDR pathways intended to create synthetic lethality in tumor cells.
Early discovery pipeline	20% Earlier-stage research assets, including undisclosed DDR targets and next-generation oncology molecules.
Research collaborations and grants	10% Non-product funding and scientific support, including grant-backed combination studies and potential partnering.

Aprea does not currently sell commercial products, so its near-term counterparties are primarily research funders,...

Future oncology treatment providersprimary
Cancer centers and oncologists would use approved therapies for patients whose tumors match the relevant genetic biomarkers.
Biomarker-defined cancer patientsprimary
Patients with DDR-related or other genetically defined tumors are the intended end users of the company’s precision oncology drugs.
Pharmaceutical licensing partnerssecondary
Larger biopharma companies may license or co-develop assets to gain access to Aprea’s synthetic lethality programs.
Research grant providerssecondary
Public funding bodies such as the National Cancer Institute support selected preclinical and combination studies.
Contract development and manufacturing partnerssecondary
Specialist vendors provide API, drug product, and clinical supply services needed to advance candidates.

Aprea is headquartered in Doylestown, Pennsylvania, and reports in U.S. dollars, but it also operates through its...

•Headquartered in Doylestown, Pennsylvania, United States
•Operates through wholly owned Swedish subsidiary Aprea AB
•Reports consolidated results in U.S. dollars
•Foreign-currency exposure arises from Swedish operations and cash balances
•Development and manufacturing are outsourced rather than tied to one region
•Clinical and research activities can span multiple countries through partners

Aprea’s strategy is to advance a focused pipeline of synthetic lethality oncology assets that target DDR pathways and...

Advance lead DDR oncology assetsshort-term

The company’s value creation depends on generating clinical proof-of-concept for its most advanced synthetic lethality programs.

Expand combination-therapy opportunitiesmedium-term

Combination regimens may improve efficacy and differentiate the assets in competitive oncology markets.

Progress early-stage pipeline assetsmedium-term

Earlier programs provide future pipeline depth and reduce dependence on a small number of candidates.

Secure non-dilutive and partner fundingshort-term

As a clinical-stage biotech with no product revenue, external capital is essential to fund development and extend runway.

Aprea faces the typical risks of a clinical-stage biotech: its programs may fail in preclinical or clinical testing,...

high

Need for additional capital

The company has incurred significant losses and has no commercial product revenue, so it must raise funds to continue development.

Scope: Corporate runway and dilution risk
Materiality: high

high

Clinical development failure

Drug candidates may not demonstrate sufficient safety, efficacy, or biomarker-driven benefit to advance.

Scope: ATRN-119, APR-1051, APR-1602
Materiality: high

high

Nasdaq continued listing compliance

Failure to meet listing requirements could lead to delisting and reduce liquidity and financing flexibility.

Scope: Public equity market access
Materiality: high

medium

Manufacturing and supply-chain dependence

The company relies on contract manufacturers for APIs and drug product, which can create quality, capacity, and timing risks.

Scope: Clinical supply and future commercial readiness
Materiality: medium

low

Foreign exchange volatility

Operations through Aprea AB create translation and remeasurement effects in consolidated U.S. dollar reporting.

Scope: Swedish subsidiary balances and expenses
Materiality: low

Accrued research and development expenses

Can materially affect quarterly R&D expense and net loss

Foreign currency translation and remeasurement

Affects other comprehensive loss and reported earnings volatility

Valuation allowance on deferred tax assets

Prevents recognition of tax benefits that would otherwise reduce losses

Grant revenue recognition

Can cause period-to-period volatility in other income

Aprea Therapeutics, Inc.

Need for additional capital

Clinical development failure

Nasdaq continued listing compliance

Manufacturing and supply-chain dependence

Foreign exchange volatility

Atara Biotherapeutics, Inc.

Kymera Therapeutics, Inc.

Aura Biosciences, Inc.

Azitra, Inc.

Protara Therapeutics, Inc.

Tyra Biosciences, Inc.